MDxHealth (NASDAQ:MDXH – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01, Zacks reports. The firm had revenue of $27.21 million for the quarter, compared to analysts’ expectations of $26.14 million.
Here are the key takeaways from MDxHealth’s conference call:
- Q2 revenue rose 16% year over year to $27.2 million and 14% sequentially, while tissue-based testing volumes recovered by more than 1,400 tests following the ExoDx integration and sales-force restructuring.
- Management reaffirmed full-year revenue guidance of $110 million to $115 million and expects to return to adjusted EBITDA profitability as it exits 2026, citing continued growth and operating discipline.
- The company completed the wind-down of its Resolve UTI business and Plano laboratory, removing a $10.4 million contingent liability; it also raised $20 million in a registered direct offering, resulting in pro forma cash of approximately $39.2 million as of June 30.
- Gross margin declined to 65.7% from 68.6% a year earlier due to test mix, while the operating loss widened to $5.1 million and adjusted EBITDA was negative $2.3 million, primarily reflecting ExoDx-related operating expenses.
- Management highlighted potential growth from the peer-reviewed PROMPT study, the planned PROTECT study in active surveillance, and artificial intelligence initiatives supporting GPS, Confirm mdx, and ExoDx, while acknowledging that 2027 visibility remains preliminary.
MDxHealth Stock Performance
Shares of NASDAQ:MDXH traded up $0.35 during midday trading on Friday, hitting $0.81. 324,724,305 shares of the stock were exchanged, compared to its average volume of 2,578,160. MDxHealth has a 52-week low of $0.40 and a 52-week high of $5.33. The business’s fifty day simple moving average is $0.47 and its two-hundred day simple moving average is $1.79. The company has a market capitalization of $40.00 million, a PE ratio of -1.24 and a beta of 1.42.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several analysts have recently commented on MDXH shares. William Blair cut MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. TD Cowen reissued a “buy” rating and set a $1.50 price target (down from $7.00) on shares of MDxHealth in a research report on Thursday, May 14th. BTIG Research reduced their price objective on MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Lake Street Capital set a $3.00 price objective on MDxHealth and gave the stock a “buy” rating in a research report on Friday. Finally, Wall Street Zen cut MDxHealth from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $2.83.
Check Out Our Latest Stock Analysis on MDXH
Trending Headlines about MDxHealth
Here are the key news stories impacting MDxHealth this week:
- Positive Sentiment: MDxHealth reported second-quarter revenue of $27.2 million, up 16% year over year and above the approximately $26.1 million analyst estimate. The company’s $0.18 per-share loss was slightly better than the $0.19 consensus cited by MarketBeat, although another estimate tracked by Zacks showed a larger expected loss of $0.12. MDxHealth Reports Second Quarter 2026 Financial Results
- Positive Sentiment: The company raised or reaffirmed an optimistic FY 2026 revenue outlook of $110 million to $115 million, well above the roughly $98.8 million consensus estimate. This suggests management expects continued commercial momentum. MDxHealth Earnings Report
- Positive Sentiment: Management discussed the results and outlook during its second-quarter earnings call, giving investors additional detail on the company’s operating performance and growth plans. MDxHealth Q2 2026 Earnings Call Transcript
- Neutral Sentiment: Trading in MDXH was temporarily paused several times under the exchange’s Limit Up-Limit Down mechanism. The halts do not represent a fundamental company announcement, but they underscore unusually high volatility and speculative trading activity.
- Negative Sentiment: MDxHealth agreed to raise $20 million through a direct share offering. The added funding may support operations and growth, but issuing new shares can dilute existing shareholders and may be contributing to the sharp price swings. MDxHealth Raises $20 Million in Direct Share Offering
About MDxHealth
MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.
MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.
Featured Stories
- Five stocks we like better than MDxHealth
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.
